Morality and Innovation: Opportunity Costs of Antibiotic Drug Pricing?

Manufacturing antibiotics is tricky: They’re as pricey to make as any other drug but, unlike meds for cancer or chronic illnesses, they’re curative. That means limited doses are required for success. Their profitability is also curbed by antibiotic resistance that forces sunsetting of old drugs for newer strains.
 
To generate innovation that combats antibiotic resistance, experts suggest luring manufacturers with longer patents and cash rewards. A few drug corporations have simply tried to ratchet up drug prices. This tactic, as seen in this case study of nitrofurantoin—an antibiotic commonly used for UTIs—raises hackles and sounds moral alarms about predatory pricing.
 
Wired

Comments +

0 comments

Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top